Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Brigham and Women's Hospital | OTHER |
| Cambridge Health Alliance | OTHER |
Not provided
Not provided
Not provided
Not provided
Using data from the Chelsea Eats program, we propose to study a randomized controlled trial in which the City of Chelsea, Massachusetts held a lottery to allocate cash benefits to its residents for ten months during the first two years of the COVID-19 pandemic. We will analyze the impact of the cash benefit on health care utilization and health.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment Group | Experimental | Participants in the treatment group received up to $400 per month. |
|
| Control Group | Active Comparator | Participants in the control group did not receive monthly cash benefits. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cash Benefit | Other | Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021. |
| Measure | Description | Time Frame |
|---|---|---|
| Emergency department use | Count of visits to the emergency department (ED) using the electronic health record | 10 months |
| Measure | Description | Time Frame |
|---|---|---|
| Behavioral health-related ED visit | Visits to the ED with a behavioral health-related diagnosis code | 10 months |
| Substance use disorder-related ED visit | Visits to the ED with a substance use disorder-related diagnosis code |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sumit Agarwal, MD, MPH | Brigham and Women's Hospital and Harvard Medical School | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Harvard Medical School | Boston | Massachusetts | 02115 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 14, 2022 | Nov 21, 2022 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D010342 | Patient Acceptance of Health Care |
| ID | Term |
|---|---|
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| No Cash Benefit | Other | No monthly cash benefit. |
|
| 10 months |
| Potentially avoidable ED visit | Visits to the ED that are potentially avoidable, categorized as avoidable according to the previously validated New York University algorithm | 10 months |
| ED visit resulting in admission to the hospital | Visits to the ED that result in a hospitalization | 10 months |
| Outpatient service use | Office visits and visits for other types of outpatient care such as imaging and procedures | 10 months |
| COVID vaccination | Binary variable for having received at least one dose of any COVID vaccine by the end of the trial period | 10 months |
| Hemoglobin A1c | Continuous measure of diabetes, using the latest available reading or result during trial period | 10 months |
| Blood pressure | Continuous measure of blood pressure, using the latest available reading or result during trial period | 10 months |
| Weight | Continuous measure of weight, using the latest available reading or result during trial period | 10 months |
| Cholesterol | Continuous measure of cholesterol, using the latest available reading or result during trial period | 10 months |